Dr Duncan F Rogers

Publications


Journals

  • Lai H; Rogers DF. (Aug 2010). New pharmacotherapy for airway mucus hypersecretion in asthma and COPD: targeting intracellular signaling pathways. J Aerosol Med Pulm Drug Deliv. 23:219-231. DOI.
  • Grandhi S; Donnelly LE; Rogers DF. (Oct 2007). Phytoceuticals: the new 'physic garden' for asthma and chronic obstructive pulmonary disease. Expert Rev Respir Med. 1:227-246. DOI.
  • Lai HY; Rogers DF. (Feb 2010). Mucus hypersecretion in asthma: intracellular signalling pathways as targets for pharmacotherapy. Curr Opin Allergy Clin Immunol. 10:67-76. DOI.
  • Rousseau K; Kirkham S; Johnson L; Fitzpatrick B; Howard M; Adams EJ; Rogers DF; Knight D; et alClegg P; Thornton DJ. (1 Aug 2008). Proteomic analysis of polymeric salivary mucins: no evidence for MUC19 in human saliva. BIOCHEM J. 413:545-552. DOI.
  • Donnelly LE; Rogers DF. (Jun 2008). Novel targets and drugs in inflammatory lung disease. Curr Opin Pharmacol. 8:219-221. DOI.
  • Rogers DF. (Sep 2007). Mucoactive agents for airway mucus hypersecretory diseases. RESPIRATORY CARE. 52:1176-1197.
  • Rogers DF. (Sep 2007). Physiology of airway mucus secretion and pathophysiology of hypersecretion. RESPIRATORY CARE. 52:1134-1149.
  • Gwilt CR; Donnelly LE; Rogers DF. (Aug 2007). The non-neuronal cholinergic system in the airways: an unappreciated regulatory role in pulmonary inflammation?. Pharmacol Ther. 115:208-222. DOI.
  • Holder E; Griesenbach U; Li S; Huang L; Rogers DF; Jeffery PK; Geddes DM; Alton EW. (Dec 2006). Intravenously administered oligonucleotides can be delivered to conducting airway epithelium via the bronchial circulation. Gene Ther. 13:1628-1638. DOI.
  • Foster KA; Adams EJ; Durose L; Cruttwell CJ; Marks E; Shone CC; Chaddock JA; Cox CL; et alHeaton C; Sutton JM; Wayne J; Alexander FC; Rogers DF. (Apr 2006). Re-engineering the target specificity of Clostridial neurotoxins - a route to novel therapeutics. Neurotox Res. 9:101-107.
  • Rogers DF; Barnes PJ. (2006). Treatment of airway mucus hypersecretion. Ann Med. 38:116-125. DOI.
  • Rogers DF. (Sep 2005). The role of airway secretions in COPD: pathophysiology, epidemiology and pharmacotherapeutic options. COPD. 2:341-353.
  • Culpitt SV; Rogers DF; Traves SL; Barnes PJ; Donnelly LE. (Jun 2005). Sputum matrix metalloproteases: comparison between chronic obstructive pulmonary disease and asthma. Respir Med. 99:703-710. DOI.
  • Rogers DF. (2005). Mucociliary dysfunction in COPD: effect of current pharmacotherapeutic options. Pulm Pharmacol Ther. 18:1-8. DOI.
  • Rogers DF. (Jun 2004). Airway mucus hypersecretion in asthma: an undervalued pathology?. Curr Opin Pharmacol. 4:241-250. DOI.
  • Culpitt SV; Rogers DF; Fenwick PS; Shah P; De Matos C; Russell RE; Barnes PJ; Donnelly LE. (Nov 2003). Inhibition by red wine extract, resveratrol, of cytokine release by alveolar macrophages in COPD. Thorax. 58:942-946.
  • Donnelly LE; Rogers DF. (Sep 2003). Antiproteases and retinoids for treatment of chronic obstructive pulmonary disease. EXPERT OPIN THER PAT. 13:1345-1372.
  • Rogers DF. (Sep 2003). Pulmonary mucus: Pediatric perspective. Pediatr Pulmonol. 36:178-188. DOI.
  • Rogers DF. (May 2003). Airway hypersecretion in allergic rhinitis and asthma: new pharmacotherapy. Curr Allergy Asthma Rep. 3:238-248.
  • Nightingale JA; Rogers DF; Barnes PJ. (Feb 2003). How to design a negative study. CHEST. 123:656-656.
  • Culpitt SV; Rogers DF; Shah P; De Matos C; Russell RE; Donnelly LE; Barnes PJ. (1 Jan 2003). Impaired inhibition by dexamethasone of cytokine release by alveolar macrophages from patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 167:24-31. DOI.
  • Rogers DF. (Jan 2003). The airway goblet cell. Int J Biochem Cell Biol. 35:1-6.
  • Donnelly LE; Rogers DF. (2003). Therapy for chronic obstructive pulmonary disease in the 21st century. Drugs. 63:1973-1998.
  • Rogers DF. (Aug 2002). Airway goblet cell hyperplasia in asthma: hypersecretory and anti-inflammatory?. Clin Exp Allergy. 32:1124-1127.
  • Rogers DF. (Jun 2002). Pharmacological regulation of the neuronal control of airway mucus secretion. Curr Opin Pharmacol. 2:249-255.
  • Culpitt SV; de Matos C; Russell RE; Donnelly LE; Rogers DF; Barnes PJ. (15 May 2002). Effect of theophylline on induced sputum inflammatory indices and neutrophil chemotaxis in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 165:1371-1376.
  • Nightingale JA; Rogers DF; Barnes PJ. (May 2002). Comparison of the effects of salmeterol and formoterol in patients with severe asthma. Chest. 121:1401-1406.
  • de Graaf W; Smith AK; Barnes PJ; Rogers DF. (Mar 2002). Mucin gene expression in human respiratory epithelial cell lines: Activation by phorbol esters and effect of a corticosteroid and cyclic AMP activating agents. BRIT J PHARMACOL. 135.
  • Pritchard K; Smith AK; Rogers DF. (2002). Measuring mucin gene expression in human airways - Northern analysis and RT-PCR. Thorac Med. 17:1-9.
  • Rogers DF. (Jan 2002). Mucoactive drugs for asthma and COPD: any place in therapy?. Expert Opin Investig Drugs. 11:15-35. DOI.
  • Fox E; Griesenbach U; Rogers DF; Huang L; Li S; Booy B; Jeffery PK; Geddes DM; et alAlton EWFW. (Dec 2001). Successful oligodeoxynucleotide transfer to the airway epithelium following intravenous delivery. THORAX. 56:2-2.
  • Rogers DF. (Mar 2001). Motor control of airway goblet cells and glands. Respir Physiol. 125:129-144.
  • Khan S; Liu YC; Khawaja AM; Manzini S; Rogers DF. (Jan 2001). Effect of the long-acting tachykinin NK(1) receptor antagonist MEN 11467 on tracheal mucus secretion in allergic ferrets. Br J Pharmacol. 132:189-196. DOI.
  • Rogers DF. (2001). Mucus hypersecretion in chronic obstructive pulmonary disease. Novartis Found Symp. 234:65-77.
  • Rogers DF. (2001). Tachykinin receptor antagonists for asthma and COPD. Expert Opin Ther Patients. 11:1097-1121.
  • Rogers DF. (Aug 2000). Mucus pathophysiology in COPD: differences to asthma, and pharmacotherapy. Monaldi Arch Chest Dis. 55:324-332.
  • Nightingale JA; Maggs R; Cullinan P; Donnelly LE; Rogers DF; Kinnersley R; Chung KF; Barnes PJ; et alAshmore M; Newman-Taylor A. (Jul 2000). Airway inflammation after controlled exposure to diesel exhaust particulates. Am J Respir Crit Care Med. 162:161-166.
  • Culpitt SV; Rogers DF. (Jul 2000). Evaluation of current pharmacotherapy of chronic obstructive pulmonary disease. Expert Opin Pharmacother. 1:1007-1020. DOI.
  • Nightingale JA; Rogers DF; Chung KF; Barnes PJ. (Feb 2000). No effect of inhaled budesonide on the response to inhaled ozone in normal subjects. Am J Respir Crit Care Med. 161:479-486.
  • Khawaja AM; Liu Y; Rogers DF. (19 Nov 1999). Effect of non-peptide tachykinin NK(1) receptor antagonists on non-adrenergic, non-cholinergic neurogenic mucus secretion in ferret trachea. Eur J Pharmacol. 384:173-181.
  • Liu YC; Khawaja AM; Rogers DF. (Nov 1999). Effect of vasoactive intestinal peptide (VIP)-related peptides on cholinergic neurogenic and direct mucus secretion in ferret trachea in vitro. BRIT J PHARMACOL. 128:1353-1359.
  • Rogers DF; Barnes PJ. (Sep 1999). COPD: new developments and therapeutic opportunities. Trends Pharmacol Sci. 20:352-354.
  • Nightingale JA; Rogers DF; Barnes PJ. (Jun 1999). Differential effect of formoterol on adenosine monophosphate and histamine reactivity in asthma. Am J Respir Crit Care Med. 159:1786-1790.
  • Rush AK; Liu YC; Price S; Barnes PJ; Rogers DF. (Mar 1999). Effect of lipopolysaccharide on mucin gene expression in rat lung in vivo. AM J RESP CRIT CARE. 159:A474-A474.
  • Lei YH; Rogers DF. (Mar 1999). Effects and interactions of opioids on plasma exudation induced by cigarette smoke in guinea pig bronchi. Am J Physiol. 276:L391-L397.
  • Nightingale JA; Cullinan P; Ashmore M; Rogers DF; Chung KF; Newman-Taylor AJ; Barnes PJ. (Mar 1999). Inflammatory effects of inhaled diesel exhaust particulates in normal subjects. AM J RESP CRIT CARE. 159:A317-A317.
  • Witherden IR; Liu YC; Goldstraw P; Ladas G; Ratcliffe C; Rogers DF; Tetley TD. (Mar 1999). Mucin gene expression and protein production by primary human alveolar type II cells compared with lung tumour cell lines in vitro. AM J RESP CRIT CARE. 159:A174-A174.
  • Khawaja AM; Liu YC; Rogers DF. (1999). Effect of fenspiride, a non-steroidal antiinflammatory agent, on neurogenic mucus secretion in ferret trachea in vitro. Pulm Pharmacol Ther. 12:363-368. DOI.
  • Rogers DF; Giembycz MA. (Dec 1998). Conquering airway inflammation in the 21st century. DRUG DISCOV TODAY. 3:532-535.
  • Nightingale JA; Rogers DF; Hart LA; Kharitonov SA; Chung KF; Barnes PJ. (Jul 1998). Effect of inhaled endotoxin on induced sputum in normal, atopic, and atopic asthmatic subjects. Thorax. 53:563-571.
  • Liu YC; Khawaja AM; Rogers DF. (Jun 1998). Effects of the cysteinyl leukotriene receptor antagonists pranlukast and zafirlukast on tracheal mucus secretion in ovalbumin-sensitized guinea-pigs in vitro. Br J Pharmacol. 124:563-571. DOI.
  • Rogers DF; Giembycz MA. (May 1998). Asthma therapy for the 21st century. Trends Pharmacol Sci. 19:160-164.
  • Ramnarine SI; Liu YC; Rogers DF. (Apr 1998). Neuroregulation of mucus secretion by opioid receptors and K(ATP) and BK(Ca) channels in ferret trachea in vitro. Br J Pharmacol. 123:1631-1638. DOI.
  • Rogers DF; Laurent GJ. (Mar 1998). New ideas on the pathophysiology and treatment of lung disease. Thorax. 53:200-203.
  • Nightingale JA; Rogers DF; Barnes PJ. (Feb 1998). Effect of repeated sputum induction on cell counts in normal volunteers. Thorax. 53:87-90.
  • Emms JC; Rogers DF. (Oct 1997). Cigarette smoke-inhibition of neurogenic bronchoconstriction in guinea-pigs in vivo: involvement of exogenous and endogenous nitric oxide. Br J Pharmacol. 122:779-785. DOI.
  • Rogers DF. (Jun 1997). In vivo preclinical test models for studying airway mucus secretion. Pulm Pharmacol Ther. 10:121-128. DOI.
  • Rogers DF. (1997). Neurogenic inflammation in lung disease: burnt out?. Inflammopharmacology. 5:319-329. DOI.
  • Newman TM; Robichaud A; Rogers DF. (Oct 1996). Microanatomy of secretory granule release from guinea pig tracheal goblet cells. Am J Respir Cell Mol Biol. 15:529-539.
  • Ramnarine SI; Haddad EB; Khawaja AM; Mak JCW; Rogers DF. (15 Jul 1996). On muscarinic control of neurogenic mucus secretion in ferret trachea. J PHYSIOL-LONDON. 494:577-586.
  • Khawaja AM; Rogers DF. (Jul 1996). Tachykinins: receptor to effector. Int J Biochem Cell Biol. 28:721-738.
  • Ramnarine SI; Khawaja AM; Barnes PJ; Rogers DF. (Jun 1996). Nitric oxide inhibition of basal and neurogenic mucus secretion in ferret trachea in vitro. Br J Pharmacol. 118:998-1002.
  • Rogers DF. (May 1996). Scorpion venoms: taking the sting out of lung disease. Thorax. 51:546-548.
  • Rogers DF; Laurent GJ. (Feb 1996). Introduction. THORAX. 51:217-217.
  • Lei YH; Barnes PJ; Rogers DF. (Jun 1995). Mechanisms and modulation of airway plasma exudation after direct inhalation of cigarette smoke. Am J Respir Crit Care Med. 151:1752-1762.
  • Rogers DF; Alton EW; Dewar A; Lethem MI; Barnes PJ. (Jan 1993). Impaired stimulus-evoked mucus secretion in cystic fibrosis bronchi. Exp Lung Res. 19:37-53.
  • Alton EW; Rogers DF; Logan-Sinclair R; Yacoub M; Barnes PJ; Geddes DM. (Dec 1992). Bioelectric properties of cystic fibrosis airways obtained at heart-lung transplantation. Thorax. 47:1010-1014.
  • Hui KP; Lötvall J; Rogers DF; Barnes PJ; Chung FK. (Oct 1992). Ovalbumin aerosol challenge in actively sensitized guinea pigs: relationship between airway microvascular leakage and airflow obstruction. Allergy. 47:527-531.
  • Kuo HP; Rohde JA; Barnes PJ; Rogers DF. (Aug 1992). Cigarette smoke-induced airway goblet cell secretion: dose-dependent differential nerve activation. Am J Physiol. 263:L161-L167.
  • Kuo HP; Rohde JA; Barnes PJ; Rogers DF. (14 May 1992). K+ channel activator inhibition of neurogenic goblet cell secretion in guinea pig trachea. Eur J Pharmacol. 215:297-299.
  • Rogers DF; Godfrey RW; Castro K; Majumdar S; Jeffery PK. (Jul 1991). Effects of a new compound (Zy 15850A) on cigarette smoke-induced bronchitis in the rat. Agents Actions. 33:358-366.
  • ROGERS DF; GODFREY RWA; CASTRO K; MAJUMDAR S; JEFFERY PK. (Jul 1991). EFFECTS OF A NEW COMPOUND (ZY-15850A) ON CIGARETTE SMOKE-INDUCED BRONCHITIS IN THE RAT. AGENTS ACTIONS. 33:359-366.
  • Barnes PJ; Boschetto P; Rogers DF; Belvisi M; Roberts N; Chung KF; Evans TW. (Dec 1990). Effects of treatment on airway microvascular leakage. Eur Respir J Suppl. 12:663s-670s.
  • Rogers DF; Dijk S; Barnes PJ. (Nov 1990). Bradykinin-induced plasma exudation in guinea-pig airways: involvement of platelet activating factor. Br J Pharmacol. 101:739-745.
  • Tokuyama K; Kuo HP; Rohde JA; Barnes PJ; Rogers DF. (Aug 1990). Neural control of goblet cell secretion in guinea pig airways. Am J Physiol. 259:L108-L115.
  • Barnes PJ; Belvisi MG; Rogers DF. (May 1990). Modulation of neurogenic inflammation: novel approaches to inflammatory disease. Trends Pharmacol Sci. 11:185-189.
  • Evans TW; Rogers DF; Belvisi MG; Rohde JA; Chung KF; Barnes PJ. (Mar 1990). Endotoxin-induced plasma exudation in guinea-pig airways in vivo and the effect of neutrophil depletion. Eur Respir J. 3:299-303.
  • Chung KF; Rogers DF; Barnes PJ; Evans TW. (Mar 1990). The role of increased airway microvascular permeability and plasma exudation in asthma. Eur Respir J. 3:329-337.
  • Rogers DF; Aursudkij B; Barnes PJ. (19 Dec 1989). Effects of tachykinins on mucus secretion in human bronchi in vitro. Eur J Pharmacol. 174:283-286.
  • ROGERS DF; TURNER NC; MARRIOTT C; JEFFERY PK. (Nov 1989). ORAL N-ACETYLCYSTEINE OR S-CARBOXYMETHYLCYSTEINE INHIBIT CIGARETTE SMOKE-INDUCED HYPERSECRETION OF MUCUS IN RAT LARYNX AND TRACHEA INSITU. EUR RESPIR J. 2:955-960.
  • Rogers DF; Barnes PJ. (29 Apr 1989). Opioid inhibition of neurally mediated mucus secretion in human bronchi. Lancet. 1:930-932.
  • ROGERS DF; BELVISI MG; AURSUDKIJ B; EVANS TW; BARNES PJ. (Dec 1988). EFFECTS AND INTERACTIONS OF SENSORY NEUROPEPTIDES ON AIRWAY MICROVASCULAR LEAKAGE IN GUINEA-PIGS. BRIT J PHARMACOL. 95:1109-1116.

Books

  • Rogers DF. Rogers DF (ed); Donnelly LE (ed). Human Airway Inflammation: Sampling techniques and analytical protocols. (2001).

Chapters in books

  • Rogers DF. Mucus Hypersecretion in COPD. In Recent Advances in Pathophysiology of COPD. 101-119. Barnes TTHPJ (ed). (2004).
  • Rogers DF. Overview of Airway Mucus Clearance. In Therapy for Mucus-Clearance Disorders. 1-27. Rubin BK (ed); van DSCP (ed). Marcel Dekker, New York (2004).
  • Nightingale JA; Rogers DF. Should drugs affecting mucus properties be used in COPD? Clinical evidence. In Clinical management of chronic obstructive pulmonary disease. 405-425. al TSE (ed). (2002).
  • Smith AK; Rogers DF. In vivo models of airway goblet cell hyperplasia and mucin gene expression. In Cilia and Mucus: From Development to Respiratory Defence. 239-251. Salathe M (ed). (2001).
  • Pritchard K; Smith AK; Rogers DF. Measurement of airway mucin gene expression. In Human Airway Inflammation: Sampling Techniques and Analytical Protocols. 285-294. Donnelly DFRLE (ed). (2001).
  • Rogers DF. Mucus regulation. In New Drugs for Asthma, Allergy and COPD. 160-164. Barnes TTHPJ (ed). (2001).
  • Rogers DF. Muscarinic control of airway mucus secretion. In Muscarinic Receptors in Airway Diseases. 175-201. al JZE (ed). (2001).

Conferences

  • Smith AK; Rogers DF. In vivo models of airway goblet cell hyperplasia and mucin gene expression. 239-251. (2001).
  • Rogers DF. Mucoactive agents for airway mucus hypersecretory diseases. 39th Conference of the Respiratory-Care-Journal. 52:1176-1197. (Sep 2007).
  • Rogers DF. Physiology of airway mucus secretion and pathophysiology of hypersecretion. 39th Conference of the Respiratory-Care-Journal. 52:1134-1149. (Sep 2007).
Share this on DeliciousTweet thisDigg thisStumble thisShare this on Facebook